Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid, Clarient, Prediction Sciences

Cepheid announced this week that it is shipping new versions of its GeneXpert system.
The company said the new system offers increased color capability, detection of up to 60 targets in one cartridge, and software for integrating laboratory information systems.

Clarient announced this week plans to commercialize a breast cancer test applicable for all stages of operable breast cancer, including lymph node-positive patients.
According to Clarient, its test, called Insight Dx Breast Cancer Profile, is the first molecular test of its kind.
Clarient holds an exclusive licensing agreement with Prediction Sciences to sell the test.
The Insight Dx Breast Cancer Profile comprises “a series of molecular assays that, when combined using Prediction Sciences' proprietary algorithm, offer information designed to help individual patients and their physicians understand the risk of recurrence and assist them in selecting the most appropriate therapy,” Clarient said in a statement.
“The profile could allow patients to avoid the toxic effects of unnecessary chemotherapy, thereby reducing the overall cost of care,” the company stated.
The Insight Dx Breast Cancer Profile will enter a competitive breast cancer recurrence testing market valued at between $300 million and $400 million annually in the US. Currently several companies, including Genomic Health, Agendia, and Exagen, market breast cancer recurrence tests.

Filed under

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.